AUS
NZ
UK
CA
USA
IND
Health
Why This ASX Biotech Share Is Suddenly Back on the Radar
May 14, 2026 10:08 AM AEST| By SamEBR Systems returned to market focus after commercial growth, expanding hospital contracts and manufacturing developments strengthened attention on the emerging healthcare technology company despite ongoing funding concerns.
Breakthrough ALS Study Pushes Neurizon Into Spotlight
May 13, 2026 07:36 PM AEST| By SamNeurizon Therapeutics advances its ALS research program with ethics approval for an oral liquid study, supporting treatment accessibility and strengthening its broader clinical development strategy.
Healthcare Jitters Deepen After Healius and CSL Shock
May 13, 2026 05:29 PM AEST| By SamHealthcare stocks on the ASX remain under pressure as Healius and CSL trigger renewed concerns around margins, labour costs, funding support and sector-wide earnings stability.
Anteris Expands US Trial Push Amid Heart Valve Focus
May 13, 2026 04:31 PM AEST| By SamAnteris Technologies Global advances its US heart valve trial strategy with fresh funding, manufacturing expansion, and regulatory momentum as clinical development activities continue to strengthen.
ASX Healthcare Stock Expands Capital Base With New Shares
May 13, 2026 11:23 AM AEST| By SamActinogen Medical expanded its quoted share base after issuing additional ordinary shares through option and convertible security exercises.
Amplia Therapeutics Expands Market Presence on ASX Stocks
May 12, 2026 05:30 PM AEST| By SamAmplia Therapeutics expanded its ASX-listed share base, reinforcing biotechnology sector momentum and highlighting continued healthcare innovation activity across Australia’s evolving equity market landscape.
Bioxyne Broadens European Presence Through German Supply Pact
May 12, 2026 02:51 PM AEST| By SamBioxyne broadens its European medicinal cannabis footprint through a major German supply agreement, supporting long-term expansion, stronger revenue visibility, and growing international market access.
CSL Shock Sends ASX Healthcare Sector Into Sharp Retreat
May 12, 2026 01:40 PM AEST| By SamCSL’s sharp decline weighed heavily on the healthcare sector while rising commodity prices supported mining and energy stocks across the australian stock market.
Why Mesoblast Could Be the ASX Biotech Stock Back in Focus
May 12, 2026 11:10 AM AEST| By SamMesoblast remains in focus as healthcare investors watch commercial progress, therapy expansion, and broader biotech sector recovery trends across the australian stock market.
Why Mesoblast Is Back in Focus Among ASX Biotech Stocks
May 12, 2026 10:02 AM AEST| By SamMesoblast is regaining investor attention as commercial progress, pipeline diversification, and broader healthcare innovation themes continue supporting interest in ASX biotech stocks.
Why 4DMedical’s CT:VQ Expansion Is Drawing Fresh ASX Attention
May 12, 2026 09:43 AM AEST| By Sam4DMedical is gaining stronger market attention as CT:VQ expansion, international regulatory progress, and ASX 200 inclusion reshape its healthcare technology growth narrative.
CSL Faces Fresh Pressure After Major Impairment Update
May 11, 2026 06:00 PM AEST| By SamCSL updates market outlook with impairment expectations, healthcare segment pressures, and operational changes as investors assess the future direction of the Australian biotech giant.
CSL Tumbles as Market Jitters Deepen Around Outlook
May 11, 2026 04:47 PM AEST| By SamCSL faced sharp market attention after guidance revisions and asset impairment concerns triggered fresh volatility across the healthcare sector within the ASX 200, ASX 100, and ASX 300.
CSL’s Stunning Slide Shakes Faith in ASX Blue Chips
May 11, 2026 03:33 PM AEST| By SamCSL’s market decline has raised fresh questions around blue-chip investing, earnings visibility, and long-term confidence within the Australian healthcare sector and broader equity market.
CSL in ASX 200 Spotlight as Healthcare Faces Changing Market Conditions
May 11, 2026 03:32 PM AEST| By SamCSL remained under extensive market pressure as healthcare sector sentiment weakened across Australian equities amid changing plasma collection conditions, capital management activity, and macroeconomic shifts.
ASX 200 Healthcare Giant CSL Faces Blue-Chip Reality Check
May 11, 2026 02:55 PM AEST| By SamCSL’s prolonged decline has reshaped market confidence as earnings downgrades, operational setbacks, and broker forecast debates continue dominating investor attention.
CSL Profit Warning, Geopolitical Tensions Hit ASX 200
May 11, 2026 02:55 PM AEST| By SamAustralian equities faced heightened volatility as CSL updates and geopolitical uncertainty weighed on healthcare, banking, and mining sectors.
ASX 200 Healthcare Giant CSL Faces Fresh Market Pressure
May 11, 2026 01:28 PM AEST| By SamCSL remains under pressure after weaker guidance and major impairment expectations raised concerns surrounding the healthcare giant’s recovery and operational outlook.
ASX 200 Healthcare Giant CSL Crashes After Guidance Shock
May 11, 2026 01:26 PM AEST| By SamCSL shares plunged after weaker earnings guidance and major impairment charges intensified concerns surrounding the healthcare giant’s recovery outlook and operational performance.
What Drove Fresh Movement in CSL Shares This Week?
May 11, 2026 01:09 PM AEST| By SamASX healthcare sector remained in focus as CSL attracted market attention following operational updates linked with impairments and revised financial targets.
Advertise your brand on Kalkine Media